1. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11 (5): 1223–1230.
2.
Anrather J, Iadecola C. Inflammation and Stroke: An Overview. Neurotherapeutics 2016; 13: 661–670.
3.
Banach M, Markuszewski L, Grzegorczyk J, Jegier B. Rola zapalenia w patogenezie miażdżycy. Przegl Epidemiol 2004; 58: 663–670.
4.
Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JRA. Low dose β blockade in acute stroke (“BEST” trial): An evaluation. Br Med J (Clin Res Ed) 1988; 296(6624): 737–741.
5.
Barreto GE, White RE, Ouyang Y, Xu L, Giffard RG. Astrocy tes: Targets for Neuroprotection in Stroke. Cent Nerv Syst Agents Med Chem 2012; 11: 164–173.
6.
Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acu te ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008; 41(16–17): 1330–1334.
7.
Bobinger T, Manaenko A, Burkardt P, Beuscher V, Sprügel MI, Roeder SS et al. Siponimod (BAF-312) Attenuates Perihe morrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke 2019; 50 (11): 3246–3254.
8.
Całkosiński I, Dobrzyński M, Całkosińska M, Seweryn E, Bronowicka-Szydełko A, Dzierzba K et al. Charakterysty ka odczynu zapalnego. Postępy Hig Med Dosw 2009; 63: 395–408.
9.
Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F et al. The early systemic prophylaxis of in-fection after stroke study: a randomized clinical trial. Stroke 2005; 36(7): 1495–1500.
10.
Członkowska A, Cyrta B, Korlak J. Immunological observa tions on patients with acute cerebral vascular disease. J Neu rol Sci 1979; 43(3): 455–464.
11.
d’Audigier C, Cochain C, Rossi E, Gue ́ rin CL, Bie`che I, Blan dinie`res A et al. Thrombin receptor PAR-1 activation on en dothelial progenitorcells enhances chemotaxis-associated genes expressionand leukocyte recruitment by a COX-2-de pendent mechanism. Angiogenesis 2015; 18: 347–359.
12.
Dziedzic T, Slowik A, Pera J, Szczudlik A. Beta-blockers re duce the risk of early death in ischemic stroke. J Neurol Sci 2007; 252(1): 53–56.
13.
Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, pla cebo-controlled, double-blind phase 2 trial. Lancet Neurol 2017; 16(3): 217–226.
14.
Ercan M, Firtina S, Konukoglu D. Comparison of plasma viscosity as a marker of endothelial dysfunction with ni tric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. Clin. Hemorheol Microcirc 2014; 57(4): 315–323.
15.
Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. Nat Rev Neurol 2015; 11: 524–535.
16.
Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A 2014; 111 (51): 18315-18320.
17.
Gromadzka G, Sarzynska-Dlugosz I, Czlonkowska A. IL1RN intron 2 polymorphism caused by variable number tandem repeats is associated with 1-year outcome in patients with ischaemic stroke. J Neurol Neurosurg Psychiatry 2007; 78(2): 183–186.
18.
Jarząbek K, Sobczyk A, Sobczyk W, Łabuzek K, Belowski D, Gabryel B. Koncepcja niestabilnej blaszki miażdżycowej i farmakologiczne strategie terapeutyczne. Chirurgia Polska 2015; 17(1–2): 49–68.
19.
Jenny NS, Callas PW, Judd SE, McClure LA, Kissela B, Zakai NA et al. Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort. Neurol 2019; 92(20): 2375–2384.
20.
Karliński M, Bembenek J, Grabska K, Kobayashi A, Baranow ska A, Litwin T et al. Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. Acta Neurol Scand 2014; 130: 305–311.
21.
Kelly P, Weimar C, Lemmens R, Murphy S, Purroy F, Arsovska A, NM Bornstein et.al. Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial. Eur Stroke J 2020; 0: 1-7.
22.
Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Ha miltonet F et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011; 77: 965–972.
23.
Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke. Stroke 2003; 34: 2543–2548.
24.
Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623–1629.
25.
Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on me chanisms of action and therapeutic uses. Semin Arthritis Rheum 2015; 45(3): 341–350.
26.
Libby P, Ridker P, Maseri A. Inflammation and Atheroscle rosis. Circulation 2002; 105: 1135–1143.
27.
Machado-Pereira M, Santos T, Ferreira L, Bernardino L, Fer reira R. Anti-Inflammatory Strategy for M2 Microglial Pola rization Using Retinoic Acid-Loaded Nanoparticles. Mediat Inflamm 2017; 2017 (Article: 6742427): 1–11.
28.
Maestrini I, Strbian D, Gautier S, Haapaniemi E, Mo ulin S, Sairanen T et al. Higher neutrophil counts beforethrombolysis for cerebral ischemia predict worse outcomes. Neurol 2015; 85(16): 1408–1416.
29.
Majid A. Neuroprotection in Stroke: Past, Present, and Futu re. ISRN Neurology 2014; 2014 (Article: 515716): 1–17.
30.
Manduteanu I, Simionescu M. Inflammation in atherosc lerosis: A cause or a result of vascular disorders? J Cell Mol Med 2012; 16: 1978–1990.
31.
Meisel C, Meisel A. Suppressing immunosuppression after stroke. N Eng J Med 2011; 365(22): 2134–2136.
32.
Mertens JC, Leenaerts D, Brouns R, Engelborghs S, Leven M, De Deyn PP et al. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is as sociated with stroke progression, outcome and blood-brain barrier dysfunction. J Thromb Haemost 2018; 16: 342–348.
33.
Montaner J, Fernandez-Cadenas I, Molina CA, Ribo M, Hu ertas R, Rosell A et al. Poststroke C-reactive protein is a po werful prognostic tool among candidates for thrombolysis. Stroke 2006; 37: 1205–1210.
34.
Morris RS, Jones PS, Alawneh JA, Hong YT, Fryer TD, Aigbirhio FI et al. Relationships between selective neuronal loss and microglial activation after ischaemic stroke in man. Brain 2018; 141: 2098–2111.
35.
Mracsko E, Veltkamp R. Neuroinflammation after intra cerebral hemorrhage. Front Cell Neurosci 2014; 8(Article 388): 1–13.
36.
Palasik W, Popow J, Lechowicz W, Fiszer U, Czlonkowska A. Prophylactic administration of intravenous immunoglo bulins in the early stage of ischemic stroke. Med Sci Monit 1999; 5(3): 528–532.
37.
Pasierski T, Andziak P. Rozwój i regresja miażdżycy. W: An giologia. Pasierski T, Gaciong Z, Torbicki A, Szmidt J (red.) Wyd. Lekarskie PZWL 2004; 50–58.
38.
Pradillo JM, Denes A, Greenhalgh AD, Boutin H, Drake C, McColl BW et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab 2012; 32(9): 1810–1819.
39.
Reinink H, de Jonge JC, Bath PM, van de Beek D, Berge E, Borregaard S et al. PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, cli nical trial with blinded outcome assessment. Eur Stroke J 2018; 3: 291–298.
40.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory therapy with ca nakinumab for atherosclerotic disease. N Eng J Med 2017; 377(12): 1119–1131.
41.
Ross R. Atherosclerosis – An inflammatory disease. N Engl J Med 1999; 340: 115–126.
42.
Sherman D, Bes A, Easton JD, Hacke W, Kaste M, Polmar SH et al. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the enlimomab acute stroke trial. Neurology 2001; 57: 1428–1434.
43.
Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Glo bal brain inflammation in stroke. Lancet Neurol 2019; 18: 1058-1066.
44.
Schroeter M, Schiene K, Kraemer M, Hagemann G, Weigel H, Eysel UT et al. Astroglial responses in photochemically induced focal ischemia of the rat cortex. Exp Brain Res 1995; 106: 1–6.
45.
Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I et al. Peroxiredoxin family proteins are key initia tors of post-ischemic inflammation in the brain. Nat Med 2012; 18(6): 911–917.
46.
Stoll G, Nieswandt B. Thrombo-inflammation in acute ischa emic stroke – implications for treatment. Nat Rev Neurol 2019; 15(8): 473–481.
47.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP et al. Efficacy and safety of low-dose colchicine after my ocardial infarction. N Eng J Med 2019; 381(26): 2497–2505.
48.
Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014; 11: 443–457.
49.
Thiel A, Radlinska BA, Paquette C, Sidel M, Soucy JP, Schir rmacher R et al. The temporal dynamics of poststroke neu roinflammation: a longitudinal diffusion tensor imaging--guided PET study with 11C-PK11195 in acute subcortical stroke. J Nucl Med 2010; 51: 1404–1412.
50.
Tiainen M, Mereroja A, Strabin D, Suvanto J, Curtze S, Linds berg PJ et al. Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke pa tients. Int J Stroke 2013; 8: 632–638.
51.
Wang L, Cao D, Wu H, Jia H, Yang C, Zhang L. Fisetin Prolon gs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Place bo-Controlled Clinical Trial. Clin and Appl Thromb Hemost 2019; 25: 1–8.
52.
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack W. C-reactive protein in healthy subjects: associations with obesity, insu lin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–978.
53.
Zhang J, Ren Q, Song Y, He M, Zeng Y, Liu Z et al. Prognostic role of neutrophil-lymphocyte ratio in patients with acute ischemic stroke. Medicine (Baltimore) 2017; 2017; 96(45): e8624
